Literature DB >> 19081679

Brief buprenorphine detoxification for the treatment of prescription opioid dependence: a pilot study.

Stacey C Sigmon1, Kelly E Dunn, Gary J Badger, Sarah H Heil, Stephen T Higgins.   

Abstract

We examined the feasibility of brief outpatient detoxification as a treatment for prescription opioid (PO) abusers. Fifteen PO-dependent adults were enrolled to receive buprenorphine stabilization, a 2-week buprenorphine taper, and subsequent naltrexone for those who completed the taper. Subjects also received behavioral therapy, urinalysis monitoring, and double-blind drug administration. Subjects provided 83.8%, 91.7% and 31.2% opioid-negative samples during stabilization, taper and naltrexone phases, respectively. Inspection of individual subject data revealed systematic differences in whether subjects successfully completed the taper without resumption of illicit opioid use. Post-hoc analyses were used to examine the characteristics of subjects who successfully completed the taper (Responders, n=5) vs. those who failed to do so (Nonresponders, n=9). These pilot data suggest a subset of PO abusers may respond to brief buprenorphine detoxification, though future efforts should aim to improve outcomes, investigate individual differences in treatment response and identify characteristics that may predict those for whom longer-term agonist treatment is warranted.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19081679      PMCID: PMC2643343          DOI: 10.1016/j.addbeh.2008.11.017

Source DB:  PubMed          Journal:  Addict Behav        ISSN: 0306-4603            Impact factor:   3.913


  58 in total

Review 1.  Major increases in opioid analgesic abuse in the United States: concerns and strategies.

Authors:  Wilson M Compton; Nora D Volkow
Journal:  Drug Alcohol Depend       Date:  2005-07-14       Impact factor: 4.492

2.  Characterizing the emerging population of prescription opioid abusers.

Authors:  Stacey C Sigmon
Journal:  Am J Addict       Date:  2006 May-Jun

3.  A controlled trial of buprenorphine treatment for opioid dependence.

Authors:  R E Johnson; J H Jaffe; P J Fudala
Journal:  JAMA       Date:  1992-05-27       Impact factor: 56.272

4.  Improvements in the community-reinforcement approach to alcoholism.

Authors:  N H Azrin
Journal:  Behav Res Ther       Date:  1976

5.  Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction.

Authors:  D R Jasinski; J S Pevnick; J D Griffith
Journal:  Arch Gen Psychiatry       Date:  1978-04

6.  Prescription opioid abuse among enrollees into methadone maintenance treatment.

Authors:  Andrew Rosenblum; Mark Parrino; Sidney H Schnoll; Chunki Fong; Carleen Maxwell; Charles M Cleland; Stephen Magura; J David Haddox
Journal:  Drug Alcohol Depend       Date:  2007-03-26       Impact factor: 4.492

7.  Naltrexone shortened opioid detoxification with buprenorphine.

Authors:  A Umbricht; I D Montoya; D R Hoover; K L Demuth; C T Chiang; K L Preston
Journal:  Drug Alcohol Depend       Date:  1999-10-01       Impact factor: 4.492

8.  Construct validity of the dependence syndrome as measured by DSM-IV for different psychoactive substances.

Authors:  A Feingold; B Rounsaville
Journal:  Addiction       Date:  1995-12       Impact factor: 6.526

Review 9.  Naltrexone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence.

Authors:  J P Gonzalez; R N Brogden
Journal:  Drugs       Date:  1988-03       Impact factor: 9.546

10.  Primary care office-based buprenorphine treatment: comparison of heroin and prescription opioid dependent patients.

Authors:  Brent A Moore; David A Fiellin; Declan T Barry; Lynn E Sullivan; Marek C Chawarski; Patrick G O'Connor; Richard S Schottenfeld
Journal:  J Gen Intern Med       Date:  2007-04       Impact factor: 5.128

View more
  14 in total

Review 1.  Opioid detoxification and naltrexone induction strategies: recommendations for clinical practice.

Authors:  Stacey C Sigmon; Adam Bisaga; Edward V Nunes; Patrick G O'Connor; Thomas Kosten; George Woody
Journal:  Am J Drug Alcohol Abuse       Date:  2012-03-12       Impact factor: 3.829

Review 2.  Buprenorphine-mediated transition from opioid agonist to antagonist treatment: state of the art and new perspectives.

Authors:  Paolo Mannelli; Kathleen S Peindl; Tong Lee; Kamal S Bhatia; Li-Tzy Wu
Journal:  Curr Drug Abuse Rev       Date:  2012-03

3.  Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial.

Authors:  Roger D Weiss; Jennifer Sharpe Potter; David A Fiellin; Marilyn Byrne; Hilary S Connery; William Dickinson; John Gardin; Margaret L Griffin; Marc N Gourevitch; Deborah L Haller; Albert L Hasson; Zhen Huang; Petra Jacobs; Andrzej S Kosinski; Robert Lindblad; Elinore F McCance-Katz; Scott E Provost; Jeffrey Selzer; Eugene C Somoza; Susan C Sonne; Walter Ling
Journal:  Arch Gen Psychiatry       Date:  2011-11-07

4.  Efficacy of Tramadol Extended-Release for Opioid Withdrawal: A Randomized Clinical Trial.

Authors:  Kelly E Dunn; D Andrew Tompkins; George E Bigelow; Eric C Strain
Journal:  JAMA Psychiatry       Date:  2017-09-01       Impact factor: 21.596

5.  Characterizing opioid withdrawal during double-blind buprenorphine detoxification.

Authors:  Kelly E Dunn; Kathryn A Saulsgiver; Mollie E Miller; Paul A Nuzzo; Stacey C Sigmon
Journal:  Drug Alcohol Depend       Date:  2015-03-12       Impact factor: 4.492

6.  Predictors of outcome after short-term stabilization with buprenorphine.

Authors:  Maureen Hillhouse; Catherine P Canamar; Walter Ling
Journal:  J Subst Abuse Treat       Date:  2012-09-26

Review 7.  The association between outpatient buprenorphine detoxification duration and clinical treatment outcomes: a review.

Authors:  Kelly E Dunn; Stacey C Sigmon; Eric C Strain; Sarah H Heil; Stephen T Higgins
Journal:  Drug Alcohol Depend       Date:  2011-07-08       Impact factor: 4.492

8.  Subtypes of nonmedical opioid users: results from the national epidemiologic survey on alcohol and related conditions.

Authors:  Li-Tzy Wu; George E Woody; Chongming Yang; Dan G Blazer
Journal:  Drug Alcohol Depend       Date:  2010-07-01       Impact factor: 4.492

9.  A comparison of buprenorphine taper outcomes between prescription opioid and heroin users.

Authors:  Suzanne Nielsen; Maureen Hillhouse; Christie Thomas; Albert Hasson; Walter Ling
Journal:  J Addict Med       Date:  2013 Jan-Feb       Impact factor: 3.702

10.  Bridging waitlist delays with interim buprenorphine treatment: initial feasibility.

Authors:  Stacey C Sigmon; Andrew C Meyer; Bryce Hruska; Taylor Ochalek; Gail Rose; Gary J Badger; John R Brooklyn; Sarah H Heil; Stephen T Higgins; Brent A Moore; Robert P Schwartz
Journal:  Addict Behav       Date:  2015-07-29       Impact factor: 3.913

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.